MedX Announces Application for Extension of Non-Brokered Private Placement

Executive Summary

• MedX Health Corp. applied to the TSX Venture Exchange for a 30‑day extension (to April 15, 2026) to close additional funding under its Series IV Convertible Loan Notes private placement.
• The initial closing on Feb 27, 2026 issued $2.7 million of notes; the extension could raise up to an additional $2.3 million.
• Proceeds will be used to redeem existing Series I notes, advance development and launch of the SIAscopy®/DermSecure® platform, and for general corporate purposes.

Key Details

• Initial Closing (Feb 27, 2026): $2,700,000 of Series IV Convertible Loan Notes issued.
• Extension Request: 30‑day extension to April 15, 2026 to complete further closings for up to an additional $2,300,000.
• Series IV Note Terms:
• Interest: 6% per annum, payable quarterly.
• Maturity: December 31, 2028.
• Conversion: Holder may convert at any time before maturity into units at $0.10 per unit.
• Unit Composition: 1 fully paid common share + ½ share purchase warrant.
• Share Purchase Warrant: Exercise price $0.125 per share; expires on maturity date.
• Agent Compensation:
• Cash commission equal to 6% of gross proceeds from unit sales introduced by the agent.
• Agent’s Warrants (non‑transferable) for additional units at $0.10, plus associated share purchase warrants at $0.125; also expire on maturity date.
• Insider Participation: Expected participation by certain insiders under exemption from formal valuation and minority shareholder approval (MI 61‑101).
• Use of Proceeds:
• Redemption of any outstanding Series I notes not converted to Series IV notes.
• Continued development of the SIAscopy® on DermSecure® telemedicine platform.
• Expansion of technology into the occupational health market.
• General corporate purposes.

Notable Quotes

• John Gevisser, CEO – MedX Health Corp.: “The extension will allow us to secure additional capital needed to accelerate our platform development and broaden our market reach while providing flexibility for insiders to participate under existing exemptions.”